 |
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
|
||
 |
 |
 |
|
|||||||
 |
|
|||||||||
 |
|
|||||||||
Alert Number 122
Date: August 19, 2024
We have published two recent reviews on the subject of the FCR+M (fludarabine, cyclophosphamide, Rituxan and mitoxantrone) clinical trial at M. D. Anderson. We are concerned that patients participating in this clinical trial were not screened by echocardiogram or MUGA scan prior to start of therapy. The guidelines for use of mitoxantrone now require that patients be pre-screened for proper cardiac function. We hope this omission will soon be corrected.
Our latest article FMC plus R - Brit. Version is a brief comparison of the M. D. Anderson approach with that taken by a British clinical trial using this drug combination. Patients recruited for the British trial are relapsed CLL patients, not chemo-naïve ones. And the British design calls for ECG, chest X-ray and even CAT scan when necessary to screen patients for cardiac function ahead of getting the drugs. The British trial design further confirms our understanding of this issue. Prudence is the better part of valor, we can see no good reason not to screening patients ahead of time for heart function.
Be well,
Chaya
____
NOTICE: This page from the Topics Alert archive was originally emailed to subscribers of Topics Alert, a free service of CLL Topics Inc. If you are not a subscriber and you wish to receive email Alerts, please register at the Topics Alert subscription page. The content of this page is intended for information only and it is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
———
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright Notice:
Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.
———
